Clinical TrialID 5621
Gemcitabine (GFF) in Patients With Pancreatic Cancer
NCT00919282
Metastatic Pancreatic Cancer
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 5621
- Evidence Id
- 5621
- Core Evidence Id
- 5621
- Source Clinical Trial Id
- 5602
- Herb2 Clinical Trial Id
- HBCT005602
- Nct Id
- NCT00919282
- Title
- Gemcitabine (GFF) in Patients With Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study Result
- No
- Study Condition
- Metastatic Pancreatic Cancer
- Study Type
- Interventional
- Study Design
- Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: gemcitabine, folinic acid, 5-FU
- Intervention Allocation
- Non_Randomized
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 78
- Outcome Measure
- overall survival, 1 year
- Sponsor Collaborator
- CONKO-Studiengruppe|Eli Lilly and Company
- Funded By
- OTHER
- Location
- Universitätsmedizin Berlin, Berlin, 13353, Germany
- Other Id
- CONKO 002 pilot
- Start Date
- 1997-09
- Primary Completion Date
- 2000-07
- Completion Date
- 2002-12
- First Posted
- 2009-06-12
- Results First Posted
- Last Update Posted
- 2009-06-12
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT00919282
- Title Cn
- Title En
- Gemcitabine (GFF) in Patients With Pancreatic Cancer
- Bilingual Status
- semi_complete